Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarker Strategies LLC

This article was originally published in Start Up

Executive Summary

Targeted cancer drugs are all the rage--and with good reason--but it remains challenging to accurately predict which patients will respond to them. BioMarker Strategies LLC has developed SnapPath, an ex vivo biomarker system that disperses solid tumor tissue in media. It then exposes live cells to growth factors and other stimuli to induce them to produce phosphoproteins and other ex vivo biomarkers to reveal the functional circuitry of the patient's tumor cells.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT037653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel